TET2 is essential for survival and hematopoietic stem cell homeostasis

Leukemia

Volumn 26, Issue 10, 2012, Pages 2216-2223

  Shide, K ^a   Kameda, T ^a   Shimoda, H ^a   Yamaji, T ^a   Abe, H ^a   Kamiunten, A ^a   Sekine, M ^a   Hidaka, T ^a   Katayose, K ^a   Kubuki, Y ^a   Yamamoto, S ^a   Miike, T ^a   Iwakiri, H ^a   Hasuike, S ^a   Nagata, K ^a   Marutsuka, K ^b   Iwama, A ^c   Matsuda, T ^d   Kitanaka, A ^a   Shimoda, K ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Animal models; Hematopoietic stem cells; Myeloproliferative neoplasms; TET2; Tumor suppressor

Indexed keywords

CELL PROTEIN; MESSENGER RNA; TEN ELEVEN TRANSLOCATION 2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL RENEWAL; CELL SURVIVAL; CONTROLLED STUDY; FETUS; FETUS CELL; GENE EXPRESSION REGULATION; GENE INSERTION; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; IN VIVO STUDY; INTRON; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

ANIMALS; CELL SURVIVAL; DNA-BINDING PROTEINS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HOMEOSTASIS; JANUS KINASE 2; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER;

EID: 84867403602     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.94     Document Type: Article

References (27)

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061. (Pubitemid 40386783)
2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148. (Pubitemid 40663494)
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790. (Pubitemid 40570926)
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397. (Pubitemid 40544655)
5. Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008; 22: 87-95.
6. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111: 3931-3940.
7. Xing S, Wanting TH, Zhao W, Ma J, Wang S, Xu X et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008; 111: 5109-5117.
8. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010; 115: 3589-3597.
9. Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010; 17: 584-596.
10. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108: 1377-1380. (Pubitemid 44232040)
11. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al. X-inactivationbased clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139-4141. (Pubitemid 43726824)
12. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110: 375-379. (Pubitemid 47026857)
13. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
14. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/ myeloproliferative neoplasms. Blood 2009; 113: 6403-6410.
15. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature genetics 2009; 41: 838-842.
16. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
17. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144-147.
18. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930-935.
19. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839-843.
20. Koh KP, Yabuuchi A, Rao S, Huang Y, Cunniff K, Nardone J et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell stem cell 2011; 8: 200-213.
21. Tang H, Araki K, Li Z, Yamamura K. Characterization of Ayu17-449 gene expression and resultant kidney pathology in a knockout mouse model. Transgenic Res 2008; 17: 599-608.
22. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11-24.
23. Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011; 20: 25-38.
24. Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011; 118: 4509-4518.
25. Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA 2011; 108: 14566-14571.
26. Li Y, Huang TT, Tang H, Yamamura KI, Pu XY. Gene expression profiling: identification of genes with altered expression in Ayu17-449 knockout mice. Genet Mol Res 2011; 10: 1533-1544.
27. James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, Tulliez M et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood 2008; 112: 2429-2438.